Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure

[1] Bayram M(2014)Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos Lung 192 197-203

[2] Dongel I(2015)Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma Lung Cancer 90 457-464

[3] Akbas A(2006)Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers Pathol Int 56 649-654

[4] Benli I(2005)Soluble mesothelin-related protein—a blood test for mesothelioma Lung Cancer 49 S109-S111

[5] Akkoyunlu ME(2011)Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma Clin Chem Lab Med 49 1721-1726

[6] Bakan ND(2013)Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology Cancer Invest 31 43-50

[7] Santarelli L(2009)Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure Cancer Epidemiol Biomarkers Prev 18 646-650

[8] Staffolani S(2002)Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 31-39

[9] Strafella E(2015)Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany Appl Immunohistochem Mol Morphol 23 118-125

[10] Maeda M(2010)Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma Lung Cancer 70 43-50

[1] Bayram M(2014)Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos Lung 192 197-203

[2] Dongel I(2015)Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma Lung Cancer 90 457-464

[3] Akbas A(2006)Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers Pathol Int 56 649-654

[4] Benli I(2005)Soluble mesothelin-related protein—a blood test for mesothelioma Lung Cancer 49 S109-S111

[5] Akkoyunlu ME(2011)Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma Clin Chem Lab Med 49 1721-1726

[6] Bakan ND(2013)Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology Cancer Invest 31 43-50

[7] Santarelli L(2009)Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure Cancer Epidemiol Biomarkers Prev 18 646-650

[8] Staffolani S(2002)Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 31-39

[9] Strafella E(2015)Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany Appl Immunohistochem Mol Morphol 23 118-125

[10] Maeda M(2010)Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma Lung Cancer 70 43-50